Is intracrinology of endometriosis relevant in clinical practice? A systematic review on estrogen metabolism
暂无分享,去创建一个
[1] V. Gomel,et al. Peritoneal fluid progesterone and progesterone resistance in superficial endometriosis lesions. , 2021, Human reproduction.
[2] Ning Ma,et al. Environmental Risk Factors for Endometriosis: An Umbrella Review of a Meta-Analysis of 354 Observational Studies With Over 5 Million Populations , 2021, Frontiers in Medicine.
[3] P. Rogers,et al. Superficial peritoneal endometriotic lesions are histologically diverse and rarely demonstrate menstrual cycle synchronicity with matched eutopic endometrium. , 2020, Human reproduction.
[4] M. Selbach,et al. mRNAs, proteins and the emerging principles of gene expression control , 2020, Nature Reviews Genetics.
[5] R. Mamillapalli,et al. Estrogen receptor-α immunoreactivity predicts symptom severity and pain recurrence in deep endometriosis. , 2020, Fertility and sterility.
[6] F. Lenfant,et al. Estrogen Receptors and Endometriosis , 2020, International journal of molecular sciences.
[7] T. Penning,et al. Aldo-keto reductase 1C3 - assessment as a new target for the treatment of endometriosis. , 2020, Pharmacological research.
[8] J. Tille,et al. Effect of local aromatase inhibition in endometriosis using a new chick embryo chorioallantoic membrane model , 2019, Journal of cellular and molecular medicine.
[9] A. Romano,et al. Local estrogen metabolism (intracrinology) in endometrial cancer: A systematic review , 2019, Molecular and Cellular Endocrinology.
[10] J. Höchel,et al. Absence of Drug‐Drug Interaction of Anastrozole on Levonorgestrel Delivered Simultaneously by an Intravaginal Ring: Results of a Phase 2 Trial , 2019, Journal of clinical pharmacology.
[11] F. Labrie. Intracrinology and menopause: the science describing the cell-specific intracellular formation of estrogens and androgens from DHEA and their strictly local action and inactivation in peripheral tissues , 2019, Menopause.
[12] D. Gibson,et al. Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders , 2018, International journal of molecular sciences.
[13] S. Xanthoulea,et al. Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery , 2018, Front. Pharmacol..
[14] Robert N. Taylor,et al. Endometriosis , 2018, Nature Reviews Disease Primers.
[15] Kazuto Ito,et al. A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients , 2017, BMC Urology.
[16] C. Becker,et al. Reevaluating response and failure of medical treatment of endometriosis: a systematic review , 2017, Fertility and sterility.
[17] N. Ács,et al. Treatment of Endometriosis‐Associated Pain with Elagolix, an Oral GnRH Antagonist , 2017, The New England journal of medicine.
[18] Mohamed Salah,et al. First Dual Inhibitors of Steroid Sulfatase (STS) and 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1): Designed Multiple Ligands as Novel Potential Therapeutics for Estrogen-Dependent Diseases. , 2017, Journal of medicinal chemistry.
[19] M. Schultze-Mosgau,et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial. , 2016, Human reproduction.
[20] R. Ferriani,et al. Effects of steroid hormone on estrogen sulfotransferase and on steroid sulfatase expression in endometriosis tissue and stromal cells , 2016, The Journal of Steroid Biochemistry and Molecular Biology.
[21] Vida Kocbek,et al. Expression of AKR1B1, AKR1C3 and other genes of prostaglandin F2α biosynthesis and action in ovarian endometriosis tissue and in model cell lines. , 2015, Chemico-biological interactions.
[22] Taisuke Mori,et al. Dienogest reduces HSD17β1 expression and activity in endometriosis. , 2015, The Journal of endocrinology.
[23] A. Genazzani,et al. Neurobiology of DHEA and effects on sexuality, mood and cognition , 2015, The Journal of Steroid Biochemistry and Molecular Biology.
[24] P. Vercellini,et al. Endometriosis: pathogenesis and treatment , 2014, Nature Reviews Endocrinology.
[25] J. Gotteland,et al. Synergistic Effects of E2MATE and Norethindrone Acetate on Steroid Sulfatase Inhibition , 2014, Reproductive sciences.
[26] A. Prentice,et al. ESHRE guideline: management of women with endometriosis. , 2014, Human reproduction.
[27] J. Donnez,et al. Differential expression of steroidogenic enzymes according to endometriosis type. , 2013, Fertility and sterility.
[28] M. Daris,et al. Identification of multiple and distinct defects in prostaglandin biosynthetic pathways in eutopic and ectopic endometrium of women with endometriosis. , 2013, Fertility and sterility.
[29] S. Ferrero,et al. Norethisterone acetate versus norethisterone acetate combined with letrozole for the treatment of ovarian endometriotic cysts: a patient preference study. , 2013, European journal of obstetrics, gynecology, and reproductive biology.
[30] T. Rižner,et al. Disturbed balance between phase I and II metabolizing enzymes in ovarian endometriosis: A source of excessive hydroxy-estrogens and ROS? , 2013, Molecular and Cellular Endocrinology.
[31] S. Ferrero,et al. Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies , 2013, Archives of Gynecology and Obstetrics.
[32] S. Bulun,et al. Aromatase inhibitors for the treatment of endometriosis. , 2012, Fertility and sterility.
[33] M. Poutanen,et al. Endometrial and endometriotic concentrations of estrone and estradiol are determined by local metabolism rather than circulating levels. , 2012, The Journal of clinical endocrinology and metabolism.
[34] H. Maia,et al. Correlation between aromatase expression in the eutopic endometrium of symptomatic patients and the presence of endometriosis , 2012, International journal of women's health.
[35] Y. Shimizu,et al. Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E₂ production in human endometriotic stromal cells in spheroid culture. , 2012, Fertility and sterility.
[36] S. Alborzi,et al. A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis , 2011, Archives of Gynecology and Obstetrics.
[37] S. Ferrero,et al. Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial , 2011, Reproductive biology and endocrinology : RB&E.
[38] J. Donnez,et al. Inhibition of steroid sulfatase decreases endometriosis in an in vivo murine model. , 2011, Human reproduction.
[39] K. Vouk,et al. Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis. , 2011, Chemico-biological interactions.
[40] D. Poirier. Contribution to the development of inhibitors of 17β-hydroxysteroid dehydrogenase types 1 and 7: Key tools for studying and treating estrogen-dependent diseases , 2011, The Journal of Steroid Biochemistry and Molecular Biology.
[41] T. Notsu,et al. Dienogest, a synthetic progestin, inhibits prostaglandin E2 production and aromatase expression by human endometrial epithelial cells in a spheroid culture system , 2011, Steroids.
[42] I. Sekine,et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. , 2010, Human reproduction.
[43] G. Camerini,et al. Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. , 2009, Human reproduction.
[44] J. Foidart,et al. Absence of aromatase protein and mRNA expression in endometriosis. , 2009, Human reproduction.
[45] B. Husen,et al. Disturbed estrogen and progesterone action in ovarian endometriosis , 2009, Molecular and Cellular Endocrinology.
[46] A. Romano,et al. Increased production of 17beta-estradiol in endometriosis lesions is the result of impaired metabolism. , 2009, The Journal of clinical endocrinology and metabolism.
[47] H. Tutill,et al. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. , 2008, Endocrine-related cancer.
[48] J. Brosens,et al. Inhibition of steroid sulphatase activity in endometriotic implants by 667 COUMATE: a potential new therapy. , 2007, Human reproduction.
[49] R. Kamps,et al. Estrogen metabolizing enzymes in endometrium and endometriosis. , 2007, Human reproduction.
[50] E. Kubista,et al. Expression of Aromatase and Estrogen Sulfotransferase in Eutopic and Ectopic Endometrium: Evidence for Unbalanced Estradiol Production in Endometriosis , 2007, Reproductive Sciences.
[51] P. Acién,et al. Aromatase expression in endometriotic tissues and its relationship to clinical and analytical findings. , 2007, Fertility and sterility.
[52] B. Husen,et al. Expression analysis of the genes involved in estradiol and progesterone action in human ovarian endometriosis , 2007, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[53] R. Auchus,et al. Deoxycorticosterone inactivation by AKR1C3 in human mineralocorticoid target tissues , 2006, Molecular and Cellular Endocrinology.
[54] S. Matsuzaki,et al. Analysis of aromatase and 17beta-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression in deep endometriosis and eutopic endometrium using laser capture microdissection. , 2006, Fertility and sterility.
[55] L. Hefler,et al. Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study. , 2005, Fertility and sterility.
[56] F. Ahsan,et al. The vagina as a route for systemic drug delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[57] H. Sasaki,et al. Gonadotropin-releasing hormone agonist inhibits estrone sulfatase expression of cystic endometriosis in the ovary. , 2004, Fertility and sterility.
[58] J. Kitawaki,et al. Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas. , 2003, Fertility and sterility.
[59] Takashi Suzuki,et al. Deficient 17β-Hydroxysteroid Dehydrogenase Type 2 Expression in Endometriosis: Failure to Metabolize 17β-Estradiol , 1998 .
[60] H. Sasano,et al. Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. , 1998, Fertility and sterility.
[61] S. Bulun,et al. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. , 1997, The Journal of clinical endocrinology and metabolism.
[62] S. Kennedy. Endometriosis , 1992, The Lancet.
[63] F. Labrie. Intracrinology , 1991, Molecular and Cellular Endocrinology.
[64] OUP accepted manuscript , 2021, Human Reproduction.
[65] A. Romano,et al. Inhibition of type 1 17β-hydroxysteroid dehydrogenase impairs the synthesis of 17β-estradiol in endometriosis lesions. , 2014, The Journal of clinical endocrinology and metabolism.
[66] A. Taherian,et al. Effects of Letrozole Compared with Danazol on Patients with Confirmed Endometriosis: A Randomized Clinical Trial , 2010 .
[67] S. Bulun,et al. Aromatase and other steroidogenic genes in endometriosis: translational aspects. , 2006, Human reproduction update.
[68] S. Soysal,et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. , 2004, Human reproduction.